Indian pharmaceutical firm Wockhardt receives Fast Track designation for novel antibiotic WCK 6777 from US FDA to treat complex infections.

Wockhardt Limited, an Indian pharmaceutical company, has received Fast Track designation from the US FDA for its novel antibiotic WCK 6777, aimed at treating complicated urinary tract and intra-abdominal infections. This once-daily β-lactam enhancer targets multi-drug-resistant Gram-negative bacteria and has shown a promising safety profile in a Phase I study. The company is also developing additional antibiotics to combat drug-resistant infections.

October 07, 2024
4 Articles

Further Reading